Apellis Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy APLS

*Your capital is at risk

$41.03

+0 (+0%)

At Close: Jul 23, 2026

Apellis Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -74.47. In total, the insiders bought 488.56K and sold 4.62M APLS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-74.47
● Buy	488.56K shares
● Sell	4.62M shares
18% Buy Activity Negligible or No Correlation
Sell Signal High Confidence May 14, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -74.47. Confidence increased due to high data reliability score of 100. Supported by overwhelming sell-side pressure (18% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
May 14, 2026 Sell	Common Stock U-Tender	Dunlop A. Sinclair Director	Director	161 567 Value: $646.3K
May 14, 2026 Sell	Stock Option (right to buy) D-Return	Dunlop A. Sinclair Director	Director	7 441 Value: $384.8K
May 14, 2026 Sell	Stock Option (right to buy) D-Return	Dunlop A. Sinclair Director	Director	5 748 Value: $344.1K
May 14, 2026 Buy	Common Stock A-Award	Chopas James George Vp/chief Accounting Officer	Officer	5 625 Value: $230.8K
May 14, 2026 Sell	Common Stock U-Tender	Chopas James George Vp/chief Accounting Officer	Officer	65 955 Value: $7
May 14, 2026 Sell	Stock Option (right to buy) D-Return	Chopas James George Vp/chief Accounting Officer	Officer	11 250 Value: $218.1K
May 14, 2026 Sell	Stock Option (right to buy) D-Return	Chopas James George Vp/chief Accounting Officer	Officer	15 114 Value: $795.9K
May 14, 2026 Sell	Stock Option (right to buy) D-Return	Chopas James George Vp/chief Accounting Officer	Officer	21 750 Value: $1.42M
May 14, 2026 Sell	Stock Option (right to buy) D-Return	Chan Gerald Director	Director	27 600 Value: $845.1K
May 14, 2026 Sell	Stock Option (right to buy) D-Return	Chan Gerald Director	Director	5 748 Value: $344.1K
May 14, 2026 Buy	Common Stock A-Award	Nicholson Nur Chief Technical Officer	Officer	45 220 Value: $1.86M
May 14, 2026 Buy	Common Stock A-Award	Nicholson Nur Chief Technical Officer	Officer	22 610 Value: $927.7K
May 14, 2026 Sell	Common Stock U-Tender	Nicholson Nur Chief Technical Officer	Officer	116 338 Value: $465.4K
May 14, 2026 Sell	Stock Option (right to buy) D-Return	Nicholson Nur Chief Technical Officer	Officer	28 367 Value: $1.88M
May 14, 2026 Sell	Stock Option (right to buy) D-Return	Nicholson Nur Chief Technical Officer	Officer	82 500 Value: $1.60M
May 14, 2026 Sell	Stock Option (right to buy) D-Return	Nicholson Nur Chief Technical Officer	Officer	50 974 Value: $1.81M
May 14, 2026 Sell	Common Stock D-Return	Dunlop A. Sinclair Director	Director	3 544 Value: $0
May 14, 2026 Sell	Common Stock U-Tender	Dolsten Mikael Director	Director	14 312 Value: $57.2K
May 14, 2026 Buy	Common Stock A-Award	Meltzer Leslie Chief Research And Development	Officer	45 220 Value: $1.86M
May 14, 2026 Sell	Stock Option (right to buy) D-Return	Fonteyne Paul R. Director	Director	5 748 Value: $344.1K
May 14, 2026 Sell	Common Stock U-Tender	Fonteyne Paul R. Director	Director	30 666 Value: $122.7K
May 14, 2026 Sell	Common Stock D-Return	Fonteyne Paul R. Director	Director	3 877 Value: $0
May 14, 2026 Sell	Stock Option (right to buy) D-Return	Meltzer Leslie Chief Research And Development	Officer	92 592 Value: $2.59M
May 14, 2026 Sell	Common Stock U-Tender	Meltzer Leslie Chief Research And Development	Officer	107 024 Value: $428.1K
May 14, 2026 Sell	Stock Option (right to buy) D-Return	Fonteyne Paul R. Director	Director	27 600 Value: $1.58M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT APELLIS PHARMACEUTICALS INC.

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal ...

Read Full Profile Here